Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teratogenic Drugs Need Better Risk Plans; FDA Seeks Advice From Advisory Cmte.

Executive Summary

Recent scientific literature shows that while most women who take drugs that are known to cause birth defects have heard about the risks, they don’t necessarily understand them or follow medical advice on not getting pregnant.

Advertisement

Related Content

REMS Strength Driven More By Drug’s Benefits Than Risks, FDA Suggests
REMS Strength Driven More By Drug’s Benefits Than Risks, FDA Suggests
Accutane iPLEDGE Program Tops CDER Ombudsman’s 2006 Complaint List

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054871

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel